The emergence of cell reprogramming technologies has accelerated the development of personalized therapies. Creative Bioarray is committed to developing the promise of cell reprogramming technologies for the treatment of neurodegenerative diseases and to helping our customers with cellular therapy studies for Parkinson's (PD) disease and Alzheimer's disease (AD).
Background
Neurodegenerative diseases are age-related brain lesions, with AD and PD being the most obvious examples. These incurable neurological disorders have a significant medical and economic impact. In this context, the development of new therapies, including regenerative medicine, may provide a new platform for research in the treatment of brain diseases. In recent years, cell reprogramming has emerged as a promising technology with great potential not only for the treatment of neurodegenerative diseases, but also for the potential of biological regeneration.
Recently, several studies have reported the clinical significance of the generation of neural cells for the treatment of aging brains, suggesting that rejuvenation through cell reprogramming may bring revolutionary treatment for the brain. In the future, a mature cell reprogramming technique is likely to rejuvenate an intact organism and provide an effective way to treat these devastating brain disorders. This approach promises to provide the ultimate therapeutic intervention for age-related (and other) brain disorders in humans.
Fig.1 In vitro rejuvenation by cell reprogramming. (López-León, 2017)
Development of New Therapies for Brain Disorders based on Cell Reprogramming
Over the years, researchers at Creative Bioarray have worked to develop a world-class cell reprogramming technologies platform and to explore new reprogramming approaches that overcome some of the inherent limitations of traditional iPSC technologies. We have developed a lineage reprogramming strategy that involves the direct transformation of one adult cell type into another through the transgene expression of multiple lineage-specific TFs. In addition, we have developed another strategy called pluripotency factor-mediated direct reprogramming that involves the use of generic TF to generate epigenetically unstable intermediates capable of differentiating adult cell types in response to specific differentiation factors. Based on the above strategies, we provide rational solutions for our clients to develop therapies for AD and PD.
- Establishing effective protocols to produce large numbers of patient-derived neural cells, specifically, induced neural stem cells (iNSC) and induced neural progenitor cells (iNPCs) for safe application in the treatment of PD, AD and other brain diseases.
- Establishing banks of induced cells to develop more practical and cost-effective methods than personalized approaches.
Advantages
- A professional research team in the field of cell biology
- Comprehensive cell reprogramming services
- Reliable experimental results delivered to customers in a short period of time
- Economical pricing
With a state-of-the-art cell reprogramming platform, Creative Bioarray provides professional technical support and scientific solutions for customers to develop new therapies for brain disorders based on cell reprogramming. We will provide meaningful data and reliable results for your research and contribute to accelerating the study on personalized regenerative medicine. If you need our services, please contact us for more details.
Reference
- López-León, M.; et al. Cell reprogramming: Therapeutic potential and the promise of rejuvenation for the aging brain. Ageing research reviews. 2017, 40: 168-181.